Suspicion of Ovarian Neoplasm in the Setting of New-Onset Ascites and Elevated CA-125: The Role of Transvaginal Ultrasound in A Secondary-Level Hospital. A Case Report
Main Article Content
Abstract
Introduction: New-onset ascites in women without known systemic disease represents a relevant clinical warning sign that requires exclusion of intra-abdominal malignancy, particularly of gynecologic origin. In secondary-level hospitals, diagnostic limitations may delay evaluation, making structured clinical reasoning essential.for timely decision-making.
Case report: A 33-year-old woman presented with progressive abdominal distension and dyspnea. Significant ascites was documented, with no history of hepatic, cardiac, or infectious disease. Transvaginal ultrasound revealed an irregular left adnexal mass measuring 5.0 × 7.0 cm associated with free fluid. Markedly elevated CA-125 levels (600 U/mL) were documented. Based on the integration of clinical findings, ultrasound features, and tumor markers, the patient was classified as high risk for ovarian malignancy (O-RADS US 5; IOTA malignant criterion M2), and was urgently referred to a tertiary-level gynecologic oncology center for definitive management.
Conclusions: The integration of clinical assessment with transvaginal ultrasound and serum biomarkers allows early suspicion of ovarian neoplasm and appropriate referral, even in a secondary-level hospital with limited diagnostic resources.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263.
II. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2021;397(10277):1240–1253.
III. Huang J, Hu W, Bottsford-Miller J, et al. Pathophysiology of malignant ascites in ovarian cancer. Cancers (Basel). 2021;13(14):3514.
IV. Colombo N, Ledermann JA, McCluggage WG, et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages (update). Ann Oncol. 2023;34(3):228–245.
V. Andreotti RF, Timmerman D, Benacerraf BR, et al. O-RADS US risk stratification system: 2022 update and management recommendations. Radiology. 2022;304(3):683–695.
VI. Van Calster B, Valentin L, Froyman W, et al. External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. BMJ. 2021;374:n1911.
VII. American College of Obstetricians and Gynecologists. Evaluation and management of adnexal masses. Practice Bulletin No. 233. Obstet Gynecol. 2021;138(3):e210–e226.
VIII. World Health Organization Classification of Tumours Editorial Board. Female genital tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2022.
IX. Kurman RJ, Shih I-M. The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. Am J Pathol. 2022;192(5):745–759.
X. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer in young women: histologic distribution and clinical behavior. Gynecol Oncol. 2023;170(2):235–242.
XI. Kinkel K, Hricak H, Lu Y, et al. Imaging features of ovarian cancer according to histologic subtype. Eur J Radiol. 2021;141:109799.
XII. Díaz-Padilla I, Razak ARA, Minig L, et al. CA-125 and ovarian cancer: current evidence and clinical implications. Crit Rev Oncol Hematol. 2021;157:103185.
XIII. National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 2024. NCCN Clinical Practice Guidelines in Oncology.